参芪扶正注射液治疗恶性胶质瘤术后临床观察
|
摘要
目的:探讨参芪扶正注射液治疗恶性胶质瘤术后的临床疗效。方法:将60例恶性胶质瘤患者随机分为治疗组和对照组各30例。对照组在术后给予常规对症支持治疗,治疗组在对照组基础上联合参芪扶正注射液治疗。治疗14天后评估2组临床疗效,比较治疗前后中医证候积分、卡氏评分(KPS)和生存质量改善率,检测T淋巴细胞亚群的变化。结果:治疗后,总有效率治疗组为9 3.33%,对照组为7 0.00%,2组比较,差异有统计学意义(P<0.05)。治疗后,2组中医证候积分均较治疗前降低(P<0.05),治疗组较对照组降低更明显(P<0.05)。治疗前,2组KPS比较无差异(P>0.05);治疗后,2组KPS均较治疗前升高,治疗组KPS较对照组升高更明显(P<0.05);生存质量改善率治疗组为80.00%,对照组为40.00%,2组比较,差异有统计学意义(P<0.05)。治疗后,对照组CD4+含量、CD4+/CD8+值与治疗前比较,差异均有统计学意义(P<0.05),对照组CD3+、CD8+含量与治疗前比较,差异均无统计学意义(P>0.05);治疗组CD3+、CD4+、CD8+含量和CD4+/CD8+值与治疗前和对照组比较,差异均有统计学意义(P<0.05)。结论:参芪扶正注射液联合常规疗法治疗恶性胶质瘤术后疗效明确,可以明显改善患者术后中医症状,提高患者术后生存质量和免疫功能。
Objective: To explore the clinical effect of Shenqi Fuzheng injection for postoperative malignant glioma. Methods:Divided 60 cases of patients with malignant glioma into the treatment group and the control group randomly, 30 cases in each group.The control group received routine symptomatic and supportive treatment after operation,while the treatment group additionally received Shenqi Fuzheng injection based on the treatment of the control group. After 14 days of treatment,evaluated the clinical effect in the two groups,compared scores of Chinese medicine syndromes,Karnofsky score(KPS) and the improvement rate of quality of life before and after treatment,and detected the change of T-lymphocyte subsets. Results:After treatment,the total effective rate was 93.33% in the treatment group and was 70.00% in the control group, the difference being significant(P < 0.05). After treatment, scores of Chinese medicine syndromes in the two groups were all decreased when compared with those before treatment(P < 0.05),and the decrease in the treatment group was more obvious than that in the control group(P < 0.05). After treatment,KPS in the two groups were all increased when compared with those before treatment,and the increase in the treatment group was more obvious than that in the control group(P <0.05). The improvement rate of quality of life was 80.00% in the treatment group and was 40.00% in the control group,the difference being significant(P < 0.05). After treatment,the comparisons of CD4+ content and value of CD4+/CD8+ in the control group before and after treatment showed significance in the difference(P < 0.05);no significant differences were found in the comparisons of contents of CD3+and CD8+in the control group before and after treatment(P > 0.05); the contents of CD3+, CD4+ and CD8+ and value of CD4+/CD8+in the treatment group showed significance in differences compared with those before treatment and in the control group(P <0.05). Conclusion:The therapy of Shenqi Fuzheng injection combined with routine therapy has a clear postoperative effect for malignant glioma,which can obviously improve Chinese medicine syndromes of patients after operation and immune function.
Objective: To explore the clinical effect of Shenqi Fuzheng injection for postoperative malignant glioma. Methods:Divided 60 cases of patients with malignant glioma into the treatment group and the control group randomly, 30 cases in each group.The control group received routine symptomatic and supportive treatment after operation,while the treatment group additionally received Shenqi Fuzheng injection based on the treatment of the control group. After 14 days of treatment,evaluated the clinical effect in the two groups,compared scores of Chinese medicine syndromes,Karnofsky score(KPS) and the improvement rate of quality of life before and after treatment,and detected the change of T-lymphocyte subsets. Results:After treatment,the total effective rate was 93.33% in the treatment group and was 70.00% in the control group, the difference being significant(P < 0.05). After treatment, scores of Chinese medicine syndromes in the two groups were all decreased when compared with those before treatment(P < 0.05),and the decrease in the treatment group was more obvious than that in the control group(P < 0.05). After treatment,KPS in the two groups were all increased when compared with those before treatment,and the increase in the treatment group was more obvious than that in the control group(P <0.05). The improvement rate of quality of life was 80.00% in the treatment group and was 40.00% in the control group,the difference being significant(P < 0.05). After treatment,the comparisons of CD4+ content and value of CD4+/CD8+ in the control group before and after treatment showed significance in the difference(P < 0.05);no significant differences were found in the comparisons of contents of CD3+and CD8+in the control group before and after treatment(P > 0.05); the contents of CD3+, CD4+ and CD8+ and value of CD4+/CD8+in the treatment group showed significance in differences compared with those before treatment and in the control group(P <0.05). Conclusion:The therapy of Shenqi Fuzheng injection combined with routine therapy has a clear postoperative effect for malignant glioma,which can obviously improve Chinese medicine syndromes of patients after operation and immune function.
引文
[1]Stupp R,Hegi ME,Mason WP,et al.Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phaseⅢstudy:5-year analysis of the EORTC-NCIC trial[J].Lancet Oncology,2009,10(5):459-466.
[2]邓艳,柯晴,毛艳.参芪扶正注射液对晚期小细胞肺癌化疗患者造血和免疫功能的干预作用[J].中国老年学杂志,2015,35(21):6142-6144.
[3]韩鲁军,张红欣,许会军,等.奥沙利铂联合参芪扶正注射液对原发性肝癌患者AFP与GP73水平的影响及临床疗效[J].现代生物医学进展,2016,16(22):4289-4291,4366.
[4]《中国中枢神经系统胶质瘤诊断和治疗指南》编写组.中国中枢神经系统胶质瘤诊断与治疗指南(2015)[J].中华医学杂志,2016,27(7):485-509.
[5]国家中医药管理局.ZY/T001.1~001.9-94中医病证诊断疗效标准[S].南京:南京大学出版社,1994:294-295.
[6]周际昌.实用肿瘤内科学[M].北京:人民卫生出版社,2010:357.
[7]Stopschinski BE,Beier CP,Beier D.Glioblastoma cancer stem cells from concept to clinical application[J].Cancer Lett,2013,338(1):32-40.
[8]谷家立,刘健,马莹,等.论中医药与恶性肿瘤的姑息治疗[J].中医药导报,2013,19(12):8-10,13.
[9]陈奕祺,李柳宁.刘伟胜中医辨证治疗脑瘤经验浅谈[J].江苏中医药,2017,49(6):17-19,22.
[10]杨金泉,何海波.黄芪的药理作用研究进展[J].医学理论与实践,2010,23(2):148-150.
[11]樊长征,洪巧瑜.党参对人体各系统作用的现代药理研究进展[J].中国医药导报,2016,13(10):39-43.
[12]张燕,夏之岷,谭延伟,等.参芪扶正注射液联合化疗对机体免疫功能的影响[J].现代中西医结合杂志,2011,20(22):2735-2737.
[2]邓艳,柯晴,毛艳.参芪扶正注射液对晚期小细胞肺癌化疗患者造血和免疫功能的干预作用[J].中国老年学杂志,2015,35(21):6142-6144.
[3]韩鲁军,张红欣,许会军,等.奥沙利铂联合参芪扶正注射液对原发性肝癌患者AFP与GP73水平的影响及临床疗效[J].现代生物医学进展,2016,16(22):4289-4291,4366.
[4]《中国中枢神经系统胶质瘤诊断和治疗指南》编写组.中国中枢神经系统胶质瘤诊断与治疗指南(2015)[J].中华医学杂志,2016,27(7):485-509.
[5]国家中医药管理局.ZY/T001.1~001.9-94中医病证诊断疗效标准[S].南京:南京大学出版社,1994:294-295.
[6]周际昌.实用肿瘤内科学[M].北京:人民卫生出版社,2010:357.
[7]Stopschinski BE,Beier CP,Beier D.Glioblastoma cancer stem cells from concept to clinical application[J].Cancer Lett,2013,338(1):32-40.
[8]谷家立,刘健,马莹,等.论中医药与恶性肿瘤的姑息治疗[J].中医药导报,2013,19(12):8-10,13.
[9]陈奕祺,李柳宁.刘伟胜中医辨证治疗脑瘤经验浅谈[J].江苏中医药,2017,49(6):17-19,22.
[10]杨金泉,何海波.黄芪的药理作用研究进展[J].医学理论与实践,2010,23(2):148-150.
[11]樊长征,洪巧瑜.党参对人体各系统作用的现代药理研究进展[J].中国医药导报,2016,13(10):39-43.
[12]张燕,夏之岷,谭延伟,等.参芪扶正注射液联合化疗对机体免疫功能的影响[J].现代中西医结合杂志,2011,20(22):2735-2737.